Efficacy of lenalidomide in multiple myeloma and myelodysplastic syndrome with deletion of 5q in a patient with pre-existing MGUS

被引：0
|
作者：
Mueller, N. Z. [1 ]
Nolte, F. [1 ]
Kreil, S. [1 ]
Hofmann, W-K [1 ]
Metzgeroth, G. [1 ]
机构：
[1] Univ Med Mannheim, Med Klin 3, Mannheim, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：149 / 150
页数：2
相关论文
共 50 条
  • [21] A NEW CRITICAL DELETION OF 5Q IN MYELODYSPLASTIC SYNDROME
    PHILLIPS, CN
    PRIEST, JH
    VOGLER, WR
    CLINICAL RESEARCH, 1984, 32 (05): : A885 - A885
  • [22] Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome with Isolated Del(5q) with Lenalidomide, Bortezomib, and Dexamethasone
    Washington, Nyomi
    Shippey, Eugen A., III
    Osswald, Michael B.
    BLOOD, 2020, 136
  • [23] Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone
    Washington, Nyomi R.
    Shippey, Eugen A.
    Osswald, Michael
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [24] Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy
    Omar A. Alkharabsheh
    Salwa S. Saadeh
    Darci L. Zblewski
    Naseema Gangat
    Kebede H. Begna
    Michelle A. Elliott
    Hassan B. Alkhateeb
    Mrinal S. Patnaik
    William J. Hogan
    Mark R. Litzow
    Aref Al-Kali
    Annals of Hematology, 2019, 98 : 331 - 337
  • [25] High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide
    Jonasova, Anna T.
    Polak, Jaroslav
    Vostry, Martin
    Kostecka, Arnost
    Bokorova, Radka
    Neuwirtova, Radana
    Siskova, Magda
    Caniga, Miroslav
    Sponerova, Dana
    Cermak, Jaroslav
    Mikulenkova, Dana
    Brezinova, Jana
    Michalova, Kyra
    Fuchs, Ota
    BLOOD, 2013, 122 (21)
  • [26] Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy
    Alkharabsheh, Omar A.
    Saadeh, Salwa S.
    Zblewski, Darci L.
    Gangat, Naseema
    Begna, Kebede H.
    Elliott, Michelle A.
    Alkhateeb, Hassan B.
    Patnaik, Mrinal S.
    Hogan, William J.
    Litzow, Mark R.
    Al-Kali, Aref
    ANNALS OF HEMATOLOGY, 2019, 98 (02) : 331 - 337
  • [27] Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program
    Abouyahya, Imane
    Alhan, Canan
    Westers, Theresia M.
    te Boekhorst, Peter A.
    Kappers-Klunne, Mies C.
    Coenen, Jules L.
    Heyning, Fenna H.
    Huls, Gerwin A.
    de Wolf, Joost T.
    Imholz, Alex L.
    Koene, Harry R.
    Veth, Gerda
    de Kruijf, Evert-Jan F. M.
    Muus, Petra
    Planken, Erwin V.
    Segeren, Christine M.
    Vasmel, Wies L.
    van der Velden, Ankie M.
    Velders, Gerjo A.
    Koedam, Jan
    Ossenkoppele, Gert J.
    van de Loosdrecht, Arjan A.
    LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 874 - 877
  • [28] A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
    Alan List
    Benjamin L. Ebert
    Pierre Fenaux
    Leukemia, 2018, 32 : 1493 - 1499
  • [29] Tetraploidy and 5q deletion in myelodysplastic syndrome: A case report
    Znoyko, Iya
    Stuart, Robert K.
    Ellingham, Tara
    Winters, Jennifer
    Wolff, Daynna J.
    Quigley, Denise I.
    CANCER GENETICS AND CYTOGENETICS, 2008, 183 (01) : 64 - 68
  • [30] Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?
    Donat Dürr
    Raffaele Daniele Siciliano
    Yvonne Hummel
    Alix O’Meara
    Anita Hirschi
    Roger Burkhard
    Hanspeter Honegger
    Annals of Hematology, 2010, 89 : 105 - 106
12345